Limited Eligibility for Lecanemab in Early Alzheimer's Patients

Only a small percentage of individuals with early Alzheimer's disease meet the eligibility criteria for the anti-amyloid monoclonal antibody treatments lecanemab and aducanumab, according to data from the Mayo Clinic Study of Aging. The study found that out of 237 participants with mild cognitive impairment or mild dementia and increased brain amyloid, only 8% qualified for a lecanemab trial and 5.1% qualified for an aducanumab trial. The researchers noted that the strict criteria, which include chronic health conditions and brain scan abnormalities, limit the number of eligible candidates. Further research is needed to assess the safety and efficacy of these treatments in larger and more diverse populations before they can be widely available to Alzheimer's patients.